Tech Company Financing Transactions
Critical Biologics Funding Round
Critical Biologics closed a $7 million Series A funding round on 2/8/2007. Investors included Morningside Group.
Transaction Overview
Company Name
Announced On
2/8/2007
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Series A
Investors
Proceeds Purpose
The funds will enable CBC to advance its lead recombinant human plasma gelsolin (rhu-pGSN) targeted for the prevention of life-threatening critical care complications associated with low plasma gelsolin levels.
Company Information
Company Status
Out of Business
Industry
Internet & IoT
Mailing Address
One Mifflin Place 400
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
Critical Biologics Corporation(CBC), based in Cambridge, MA, is a development stage biotechnology company committed to making innovative products available to address significant unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
James Fordyce
Chief Executive Officer
Ashleigh Palmer
Chief Medical Officer
Richard Straube
Browse more venture capital transactions:
Prev: 2/7/2007: Side Step venture capital transaction
Next: 2/8/2007: Targeted Growth venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs